These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23927675)

  • 21. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
    Cook DM; Gurugubelli RK; Bero LA
    Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Value of the Black Box Warning in Dermatology.
    Winterfield L; Vleugels RA; Park KK
    J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between FDA black box warnings and Medicare formulary coverage changes.
    Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
    Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in Incident Varenicline Prescribing Among Veterans Following the US Food and Drug Administration Drug Safety Warnings.
    Gerlach LB; Van T; Kim HM; Chang MM; Bohnert KM; Zivin K
    J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936245
    [No Abstract]   [Full Text] [Related]  

  • 26. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
    Minutolo R; Garofalo C; Chiodini P; Aucella F; Del Vecchio L; Locatelli F; Scaglione F; De Nicola L
    Nephrol Dial Transplant; 2021 Jan; 36(2):267-274. PubMed ID: 32829405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections.
    Cowart K; Worley M; Rouby NE; Sando K
    Ann Pharmacother; 2019 Dec; 53(12):1192-1199. PubMed ID: 31319681
    [No Abstract]   [Full Text] [Related]  

  • 28. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
    Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
    Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.
    Hendrick F; Davidoff AJ; Zeidan AM; Gore SD; Baer MR
    Medicare Medicaid Res Rev; 2014; 4(4):. PubMed ID: 25485173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
    Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
    Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benzodiazepines: Thinking outside the black box.
    Pergolizzi JV; LeQuang JA; Raffa RB
    J Clin Pharm Ther; 2021 Jun; 46(3):554-559. PubMed ID: 33347636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoiesis-stimulating agents and thrombotic events in dialysis patients.
    Suttorp MM; Hoekstra T; Ocak G; van Diepen AT; Ott I; Mittelman M; Rabelink TJ; Krediet RT; Dekker FW
    Thromb Res; 2014 Nov; 134(5):1081-6. PubMed ID: 25242244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories.
    Chan Q; Chan A
    J Oncol Pharm Pract; 2011 Dec; 17(4):350-9. PubMed ID: 20659968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial.
    Saglimbene V; Palmer SC; Craig JC; Ruospo M; Nicolucci A; Tonelli M; Johnson D; Lucisano G; Williams G; Valentini M; D'Alonzo D; Pellegrini F; Strippoli P; Salomone M; Santoro A; Maffei S; Hegbrant J; Tognoni G; Strippoli GF;
    PLoS One; 2017; 12(3):e0172735. PubMed ID: 28249030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluctuations of haemoglobinaemia in chronic haemodialysis patients.
    De Meester J; Maes B; De Vriese A; De Moor B; Donck J; Helbert M; Bammens B; Jamar S
    Acta Clin Belg; 2011; 66(2):123-8. PubMed ID: 21630609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The "black box" warning and allergy drugs.
    Aaronson DW
    J Allergy Clin Immunol; 2006 Jan; 117(1):40-4. PubMed ID: 16387582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up.
    Malyszko J; Drozdz M; Zolkiewicz A; Rutkowski B
    Int Urol Nephrol; 2014 Jan; 46(1):71-82. PubMed ID: 23136027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
    Luo J; Jensen DE; Maroni BJ; Brunelli SM
    Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.
    Minutolo R; Bolasco P; Chiodini P; Sposini S; Borzumati M; Abaterusso C; Mele AA; Santoro D; Canale V; Santoboni A; Filiberti O; Fiorini F; Mura C; Imperiali P; Borrelli S; Russo L; De Nicola L; Russo D
    Clin Drug Investig; 2017 Oct; 37(10):965-973. PubMed ID: 28779268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.